It’s the end of the road for Rubius Therapeutics, a biotech that previously wanted to develop cellular therapies for rare diseases, cancer and autoimmune diseases. After a last-ditch effort last year ...

Cell therapy is one of the big ideas in biotech. Entrepreneurs have become captivated by possibilities of engineering white blood cells so they can be re-infused into patients and fight cancer. One ...

Rubius Therapeutics Inc. has raised $120 million on the promise that its technology for using cells to treat disease will lead to new ways to attack cancer, infections, rare disorders and other ...

Rubius Therapeutics went public in 2018 at a $2 billion valuation — the largest biotech stock market debut at that time. On Wednesday, the company — battered down to a market value of $15 million — ...